Lifeboat Foundation

Huntington’s disease (HD) is a neurological disorder that causes progressive loss of movement, coordination and cognitive function. It is caused by a mutation in a single gene called huntingtin (HTT). More than 200,000 people worldwide live with the genetic condition, approximately 30,000 in the United States. More than a quarter of a million Americans are at risk of inheriting HD from an affected parent. There is no cure.

But in a new study, published December 12, 2022 in Nature Neuroscience, researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe using RNA-targeting CRISPR/Cas13D technology to develop a new therapeutic strategy that specifically eliminates toxic RNA that causes HD.

CRISPR is known as a genome-editing tool that allows scientists to add, remove or alter genetic material at specific locations in the genome. It is based on a naturally occurring immune defense system used by bacteria. However, current strategies run the risk of off-target edits at unintended sites that may cause permanent and inheritable chromosomal insertions or genome alterations. Because of this, significant efforts have focused on identifying CRISPR systems that target RNA directly without altering the genome.

An international research team led by Dr. Ana Guadaño at the Alberto Sols Biomedical Research Institute (IIBM, a combined CSIC-UAM center) and involving the Complutense University of Madrid (UCM), used CRISPR gene editing techniques to incorporate into mice a mutation of the MCT8 protein responsible for transporting thyroid hormones to the interior of the cell.

Patients with mutations in this protein suffer from Allan-Herndon-Dudley syndrome, a rare disease that takes the form of serious neurological alterations, in which each patient may reveal a different mutation of MCT8.

This study, published in Neurobiology of Disease, describes the first avatar model for the disease—in other words, the first animal model with the same genetic alteration as various patients.

These genetically engineered plants can take over the work of 30 houseplants.

A bioengineered plant is able to clean the air by doing the work of over 30 houseplantsIt could be the start of a bold new industry that develps over the next 15 to 20 years.

The Neo P1 is the first of its kind.

Continue reading “Plant-based air purifiers are coming to your home — The Blueprint” »

Northwestern University researchers have discovered a previously unknown mechanism that drives aging.

In a new study, researchers used artificial intelligence to analyze data from a wide variety of tissues, collected from humans, mice, rats and killifish. They discovered that the length of genes can explain most molecular-level changes that occur during aging.

All cells must balance the activity of long and short genes. The researchers found that longer genes are linked to longer lifespans, and shorter genes are linked to shorter lifespans. They also found that aging genes change their activity according to length. More specifically, aging is accompanied by a shift in activity toward short genes. This causes the gene activity in cells to become unbalanced.

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Continue reading “Bacteria From An Olympic Weightlifter Improves Muscle Mass And Physical Function (In Mice)” »

Northwestern University researchers have discovered a previously unknown mechanism that drives aging.

In a new study, researchers used artificial intelligence to analyze data from a wide variety of tissues, collected from humans, mice, rats and killifish. They discovered that the length of genes can explain most molecular-level changes that occur during aging.

Continue reading “Aging is driven by unbalanced genes” »

Tournament selection, roulette selection, mutation, crossover — all processes used in genetic algorithms. Dr Alex Turner explains using the Knapsack Problem.

https://www.facebook.com/computerphile.
https://twitter.com/computer_phile.

Continue reading “The Knapsack Problem & Genetic Algorithms — Computerphile” »

Discusses the possibility of Femtotech and the technological possibilities it may unlock. Not long ago nanotechnology was a fringe topic; now it’s a flourishing engineering field, and fairly mainstream. For example, while writing this article, I happened to receive an email advertisement for the “Second World Conference on Nanomedicine and Drug Delivery,” in Kerala, India. It wasn’t so long ago that nanomedicine seemed merely a flicker in the eyes of Robert Freitas and a few other visionaries!

But nano is not as small as the world goes. A nanometer is 10–9 meters – the scale of atoms and molecules. A water molecule is a bit less than one nanometer long, and a germ is around a thousand nanometers across. On the other hand, a proton has a diameter of a couple femtometers – where a femtometer, at 10–15 meters, makes a nanometer seem positively gargantuan. Now that the viability of nanotech is widely accepted (in spite of some ongoing heated debates about the details), it’s time to ask: what about femtotech? Picotech or other technologies at the scales between nano and femto seem relatively uninteresting, because we don’t know any basic constituents of matter that exist at those scales. But femtotech, based on engineering structures from subatomic particles, makes perfect conceptual sense, though it’s certainly difficult given current technology.

Continue reading “Hugo de Garis — From Nanotech to Femtotech — There’s Plenty More Room at the Bottom” »

A new study from Tel Aviv University proposes a novel AIDS treatment that could be turned into a vaccine or a one-time treatment for HIV patients. The research explored modifying type B white blood cells in the patient’s body to release anti-HIV antibodies in response to the virus. Dr. Adi Barzel and Ph.D. student Alessio Nehmad led the study, which was conducted in partnership with the Sourasky Medical Center (Ichilov), the George S. Wise department of life sciences, and the Dotan Center for Advanced Therapies. The study was carried out in cooperation with other researchers from Israel and the United States. The findings were published recently in the renowned journal Nature Biotechnology.

Many AIDS patients’ lives have improved during the past two decades as a result of the administration of medicines that have transformed the condition from fatal to chronic. However, we have a long way to go before finding a medication that can offer patients a permanent cure. Dr. Barzel’s laboratory pioneered one feasible method, a one-time injection. His team devised a technology that employs type B white blood cells that are genetically altered within the patient’s body to release neutralizing antibodies against the HIV virus, which causes the disease.

B cells are white blood cells that produce antibodies against viruses, bacteria, and other pathogens. Bone marrow is where B cells are formed. When they mature, B cells move into the blood and lymphatic system and from there to the different body parts.